Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.25
BCRX's Cash to Debt is ranked lower than
71% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. BCRX: 2.25 )
Ranked among companies with meaningful Cash to Debt only.
BCRX' s 10-Year Cash to Debt Range
Min: 0.94  Med: 10000.00 Max: 11087.67
Current: 2.25
0.94
11087.67
Equity to Asset 0.50
BCRX's Equity to Asset is ranked lower than
69% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. BCRX: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
BCRX' s 10-Year Equity to Asset Range
Min: -0.23  Med: 0.70 Max: 0.98
Current: 0.5
-0.23
0.98
F-Score: 3
Z-Score: 3.88
M-Score: -1.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -311.12
BCRX's Operating margin (%) is ranked lower than
68% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -71.01 vs. BCRX: -311.12 )
Ranked among companies with meaningful Operating margin (%) only.
BCRX' s 10-Year Operating margin (%) Range
Min: -17879.61  Med: -296.50 Max: -18.42
Current: -311.12
-17879.61
-18.42
Net-margin (%) -295.81
BCRX's Net-margin (%) is ranked lower than
67% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. BCRX: -295.81 )
Ranked among companies with meaningful Net-margin (%) only.
BCRX' s 10-Year Net-margin (%) Range
Min: -17170.39  Med: -289.91 Max: -18.03
Current: -295.81
-17170.39
-18.03
ROE (%) -81.57
BCRX's ROE (%) is ranked lower than
75% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -30.92 vs. BCRX: -81.57 )
Ranked among companies with meaningful ROE (%) only.
BCRX' s 10-Year ROE (%) Range
Min: -544.61  Med: -40.74 Max: -8.43
Current: -81.57
-544.61
-8.43
ROA (%) -42.61
BCRX's ROA (%) is ranked lower than
63% of the 848 Companies
in the Global Biotechnology industry.

( Industry Median: -26.61 vs. BCRX: -42.61 )
Ranked among companies with meaningful ROA (%) only.
BCRX' s 10-Year ROA (%) Range
Min: -67.46  Med: -33.33 Max: -7.68
Current: -42.61
-67.46
-7.68
ROC (Joel Greenblatt) (%) -13933.64
BCRX's ROC (Joel Greenblatt) (%) is ranked lower than
89% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. BCRX: -13933.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BCRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -15669.01  Med: -339.24 Max: -43.48
Current: -13933.64
-15669.01
-43.48
Revenue Growth (3Y)(%) -23.10
BCRX's Revenue Growth (3Y)(%) is ranked lower than
70% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. BCRX: -23.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BCRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -13.60 Max: 430.1
Current: -23.1
0
430.1
EBITDA Growth (3Y)(%) -19.70
BCRX's EBITDA Growth (3Y)(%) is ranked lower than
70% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. BCRX: -19.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BCRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -41.9  Med: -8.90 Max: 64.5
Current: -19.7
-41.9
64.5
EPS Growth (3Y)(%) -18.60
BCRX's EPS Growth (3Y)(%) is ranked lower than
65% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. BCRX: -18.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BCRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -38.4  Med: -5.10 Max: 52.9
Current: -18.6
-38.4
52.9
» BCRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

BCRX Guru Trades in

Q1 2014

BCRX Guru Trades in Q1 2014

George Soros 59,700 sh (New)
Jim Simons 90,514 sh (New)
» More
Q2 2014

BCRX Guru Trades in Q2 2014

George Soros Sold Out
Jim Simons Sold Out
» More
Q1 2015

BCRX Guru Trades in Q1 2015

Jim Simons 32,403 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with BCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 17.42
BCRX's P/B is ranked lower than
90% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: 4.68 vs. BCRX: 17.42 )
Ranked among companies with meaningful P/B only.
BCRX' s 10-Year P/B Range
Min: 1.04  Med: 5.02 Max: 122.5
Current: 17.42
1.04
122.5
P/S 63.81
BCRX's P/S is ranked lower than
82% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.51 vs. BCRX: 63.81 )
Ranked among companies with meaningful P/S only.
BCRX' s 10-Year P/S Range
Min: 0.73  Med: 7.19 Max: 2000
Current: 63.81
0.73
2000
Current Ratio 1.32
BCRX's Current Ratio is ranked lower than
84% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. BCRX: 1.32 )
Ranked among companies with meaningful Current Ratio only.
BCRX' s 10-Year Current Ratio Range
Min: 1.32  Med: 7.20 Max: 39.53
Current: 1.32
1.32
39.53
Quick Ratio 1.30
BCRX's Quick Ratio is ranked lower than
79% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. BCRX: 1.30 )
Ranked among companies with meaningful Quick Ratio only.
BCRX' s 10-Year Quick Ratio Range
Min: 1.3  Med: 7.20 Max: 39.53
Current: 1.3
1.3
39.53
Days Inventory 1.00
BCRX's Days Inventory is ranked higher than
99% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 116.21 vs. BCRX: 1.00 )
Ranked among companies with meaningful Days Inventory only.
BCRX' s 10-Year Days Inventory Range
Min: 252.26  Med: 692.66 Max: 15234.51
Current: 1
252.26
15234.51
Days Sales Outstanding 120.28
BCRX's Days Sales Outstanding is ranked lower than
80% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.10 vs. BCRX: 120.28 )
Ranked among companies with meaningful Days Sales Outstanding only.
BCRX' s 10-Year Days Sales Outstanding Range
Min: 44.54  Med: 170.94 Max: 72039.47
Current: 120.28
44.54
72039.47

Valuation & Return

vs
industry
vs
history
Price/Net Cash 516.00
BCRX's Price/Net Cash is ranked lower than
99% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 8.45 vs. BCRX: 516.00 )
Ranked among companies with meaningful Price/Net Cash only.
BCRX' s 10-Year Price/Net Cash Range
Min: 0.61  Med: 11.59 Max: 315
Current: 516
0.61
315
Price/Net Current Asset Value 70.36
BCRX's Price/Net Current Asset Value is ranked lower than
95% of the 533 Companies
in the Global Biotechnology industry.

( Industry Median: 7.60 vs. BCRX: 70.36 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BCRX' s 10-Year Price/Net Current Asset Value Range
Min: 0.59  Med: 6.28 Max: 76.83
Current: 70.36
0.59
76.83
Price/Tangible Book 17.39
BCRX's Price/Tangible Book is ranked lower than
86% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 5.78 vs. BCRX: 17.39 )
Ranked among companies with meaningful Price/Tangible Book only.
BCRX' s 10-Year Price/Tangible Book Range
Min: 0.33  Med: 4.33 Max: 121.33
Current: 17.39
0.33
121.33
Price/Median PS Value 8.95
BCRX's Price/Median PS Value is ranked lower than
96% of the 539 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. BCRX: 8.95 )
Ranked among companies with meaningful Price/Median PS Value only.
BCRX' s 10-Year Price/Median PS Value Range
Min: 0.13  Med: 3.86 Max: 139.71
Current: 8.95
0.13
139.71
Earnings Yield (Greenblatt) (%) -4.19
BCRX's Earnings Yield (Greenblatt) (%) is ranked higher than
55% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. BCRX: -4.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BCRX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -4.3  Med: 502.80 Max: 1563.9
Current: -4.19
-4.3
1563.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BO1.Germany,
Biocryst Pharmaceuticals Inc. is a Delaware corporation originally founded in 1986. The Company is engaged in the design, optimization and development of novel drugs that block key enzymes involved in the pathogenesis of diseases. It integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. It uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include Peramivir, BCX4161, Two 2nd generation HAE compounds, BCX4430, Forodesine and Ulodesine. Peramivir is a neuraminidase inhibitor for the treatment of patients with influenza and a potent, intravenously administered antiviral agent that rapidly delivers high plasma concentrations to the sites of infection. BCX4161 is a novel, selective inhibitor of plasma kallikrein in development as an orally-administered treatment for the prevention of attacks in patients with Hereditary Angioedema. Forodesine is a PNP inhibitor in development as a treatment for cancer. Ulodesine is a PNP inhibitor developed as a once-daily oral, chronic treatment for gout. The Company's product candidates are subject to extensive and rigorous domestic government regulations prior to commercialization.
» More Articles for BCRX

Headlines

Articles On GuruFocus.com
comment on BCRX Mar 02 2013 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 2,500 Shares Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares Jun 04 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares May 05 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares Apr 30 2010 

More From Other Websites
BioCryst Pharm upgraded by BofA/Merrill Jun 30 2015
Watch out! These 2 stocks are in jeopardy: Pro Jun 25 2015
2 Stocks to fall Jun 23 2015
Tekmira Tumbles On Ominous Signs For Ebola Drug Jun 19 2015
Strength Seen in BioCryst (BCRX): Stock Rises 9.9% - Tale of the Tape Jun 19 2015
BioCryst to Present at the JMP Securities Life Sciences Conference Jun 18 2015
BioCryst to Present at the JMP Securities Life Sciences Conference Jun 18 2015
Durham's BioCryst cuts $45 million deal with Australian firm Jun 17 2015
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jun 17 2015
BioCryst Licenses Worldwide Rights to Commercialize RAPIVAB(R) Influenza Treatment to CSL Limited Jun 17 2015
BioCryst Licenses Worldwide Rights to Commercialize RAPIVAB(R) Influenza Treatment to CSL Limited Jun 17 2015
RA Capital Management returns an estimated 10.09% for May Jun 03 2015
BioCryst to Present at the Jefferies 2015 Healthcare Conference May 26 2015
BioCryst to Present at the Jefferies 2015 Healthcare Conference May 26 2015
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 22 2015
BIOCRYST PHARMACEUTICALS INC Financials May 15 2015
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 13 2015
BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX7353 for the Treatment of Hereditary... May 13 2015
BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX7353 for the Treatment of Hereditary... May 13 2015
Oppenheimer Reviews BioCryst Earnings May 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK